PURPOSE: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. METHODS: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). RESULTS: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 +/- 0.94 SD, vs 0.41 +/- 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 +/- 1.49 SD, vs 0.29 +/- 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). CONCLUSION: RRM2 gene and protein expression varies by tumor type.
PURPOSE: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. METHODS:Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). RESULTS:Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 +/- 0.94 SD, vs 0.41 +/- 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 +/- 1.49 SD, vs 0.29 +/- 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). CONCLUSION:RRM2 gene and protein expression varies by tumor type.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Jeremy D Heidel; Joanna Yi-Ching Liu; Yun Yen; Bingsen Zhou; Bret S E Heale; John J Rossi; Derek W Bartlett; Mark E Davis Journal: Clin Cancer Res Date: 2007-04-01 Impact factor: 12.531
Authors: Steven Attia; Jill Kolesar; Michelle R Mahoney; Henry C Pitot; Daniel Laheru; James Heun; Wei Huang; Jens Eickhoff; Charles Erlichman; Kyle D Holen Journal: Invest New Drugs Date: 2008-02-16 Impact factor: 3.850
Authors: Mark A Rubin; Maciej P Zerkowski; Robert L Camp; Rainer Kuefer; Matthias D Hofer; Arul M Chinnaiyan; David L Rimm Journal: Am J Pathol Date: 2004-03 Impact factor: 4.307
Authors: William R Schelman; Sherry Morgan-Meadows; Rebecca Marnocha; Fred Lee; Jens Eickhoff; Wei Huang; Marcia Pomplun; Zhisheng Jiang; Dona Alberti; Jill M Kolesar; Percy Ivy; George Wilding; Anne M Traynor Journal: Cancer Chemother Pharmacol Date: 2008-12-13 Impact factor: 3.333
Authors: Matheus Lohan-Codeço; Maria Luísa Barambo-Wagner; Luiz Eurico Nasciutti; Luis Felipe Ribeiro Pinto; Nathalia Meireles Da Costa; Antonio Palumbo Journal: Cell Mol Life Sci Date: 2022-02-03 Impact factor: 9.261
Authors: Fabio Parisi; Ana M Gonzalez; Yasmine Nadler; Robert L Camp; David L Rimm; Harriet M Kluger; Yuval Kluger Journal: Breast Cancer Res Date: 2010-09-01 Impact factor: 6.466
Authors: Jennifer Wagner; Nathan Damaschke; Bing Yang; Matthew Truong; Chad Guenther; Johnathon McCormick; Wei Huang; David Jarrard Journal: PLoS One Date: 2015-04-15 Impact factor: 3.240